3 hours ago
1
CR/iStock via Getty Images
The U.S. FDA has begun a crackdown on illegally imported active pharmaceutical ingredients used to make GLP-1 weight loss drugs.
Although Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) market their own GLP-1 obesity therapies, Wegovy (semaglutide) and Zepbound (tirzepatide), the two companies
English (US) ·